PH Therapy Riociguat to Be Tested on Patients with dcSSc
Those in the Scleroderma community are taking note of recent news that Bayer HealthCare will be initiating a randomized, double-blind, placebo-controlled, Phase II clinical study to investigate efficacy and safety of riociguat in patients suffering from diffuse cutaneous systemic sclerosis (dcSSc), according to an announcement by the company. The study is…